Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
Calgary, Alberta – October 6, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech,...
Marvel Biosciences Fait Le Point Sur Un Placement Privé Pouvant Atteindre 3 Millions De Dollars
Calgary (Alberta), 17 septembre 2026 – Marvel Biosciences Corp. (TSXV : MRVL; OTCQB : MBCOF) (« Marvel » ou la « Société ») a annoncé aujourd’hui que, à la suite de ses communiqués de presse des 16 juillet 2026, 19 août 2026 et 9 septembre 2026, elle entend réaliser un placement privé sans courtier (le « Placement ») d’unités de la Société (les « Unités ») au prix de 0,15 $ par Unité. Le...
Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
Calgary, Alberta ‐ September 17, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August 19, 2026 and September 9, 2026 press releases, it intends to complete a non‐brokered private placement offering (the “Offering”) of units of the Company (“Units”) at a price of $0.15 per Unit. The Offering will be for a...
Marvel Biosciences Annonce la Prolongation de la Date Limite de Clôture du Placement Privé
Ne pas distribuer aux services de presse américains ni diffuser aux États-Unis Calgary (Alberta), 9 septembre 2026– Marvel Biosciences Corp. (TSXV : MRVL; OTCQB : MBCOF) (« Marvel » ou la « Société ») annonce avoir obtenu l’approbation de la Bourse de croissance TSX (« TSXV ») afin de prolonger la date limite de clôture de son placement privé annoncé précédemment (voir les communiqués de presse...
Marvel Biosciences Announces Extension to Closing Date of Private Placement
Calgary, Alberta ‐ September 9, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture Exchange (“TSXV”) to extend the closing deadline of its previously announced private placement (see July 16, 2026 and August 19, 2026 press releases) (the “Offering”). The deadline by which the Company must file its...
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta, Canada, September 1, 2026 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 50,001 deferred share units (“DSUs”) to Marvel’s three independent directors, in lieu of cash payment for directors’ fees. The DSUs will all vest on September 1, 2027. Vested DSUs shall be...
Marvel Biosciences Expands Private Placement to Quebec
Calgary, Alberta ‐ August 19, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private placement (see July 16, 2026 press release) to investors resident in the Province of Quebec. There is an amended and restated offering document related to this Offering dated August 19, 2026 that can be accessed under...
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
Calgary, Alberta – August 5, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce positive results from its preclinical Fragile X study conducted through the...
Marvel Biosciences Announces Private Placement Up to $3 Million
Calgary, Alberta ‐ July 16, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non‐brokered private placement offering (the “Offering”) of units of the Company (“Units”) at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross proceeds of $1,500,000, and up a maximum of...
New Autism Research to be Presented at European Purine Scientific Meeting
Calgary, Alberta – June 26, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr....